JP2008519783A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519783A5 JP2008519783A5 JP2007540535A JP2007540535A JP2008519783A5 JP 2008519783 A5 JP2008519783 A5 JP 2008519783A5 JP 2007540535 A JP2007540535 A JP 2007540535A JP 2007540535 A JP2007540535 A JP 2007540535A JP 2008519783 A5 JP2008519783 A5 JP 2008519783A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- hydrogen
- alkyl
- phenyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 60
- 229910052739 hydrogen Inorganic materials 0.000 claims 39
- 239000001257 hydrogen Substances 0.000 claims 39
- 150000002431 hydrogen Chemical group 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 229910052731 fluorine Inorganic materials 0.000 claims 25
- 229910052801 chlorine Inorganic materials 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 230000002265 prevention Effects 0.000 claims 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 12
- 229910052794 bromium Inorganic materials 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 229910052740 iodine Inorganic materials 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 238000004519 manufacturing process Methods 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 9
- -1 methoxy, ethoxy Chemical group 0.000 claims 9
- 210000000056 organ Anatomy 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 208000028867 ischemia Diseases 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- 206010019280 Heart failures Diseases 0.000 claims 6
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 6
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 6
- 238000001356 surgical procedure Methods 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 230000002093 peripheral effect Effects 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 3
- 230000009692 acute damage Effects 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 208000015114 central nervous system disease Diseases 0.000 claims 3
- 230000009693 chronic damage Effects 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 230000010410 reperfusion Effects 0.000 claims 3
- 208000003663 ventricular fibrillation Diseases 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000003495 Coccidiosis Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 208000007530 Essential hypertension Diseases 0.000 claims 2
- 208000010496 Heart Arrest Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- 206010023076 Isosporiasis Diseases 0.000 claims 2
- 206010023421 Kidney fibrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 230000009787 cardiac fibrosis Effects 0.000 claims 2
- 231100000457 cardiotoxic Toxicity 0.000 claims 2
- 230000001451 cardiotoxic effect Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 2
- 230000037356 lipid metabolism Effects 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 210000001835 viscera Anatomy 0.000 claims 2
- DWQKZCIMVWJIBS-UHFFFAOYSA-N 4-(1,1-dioxo-1,2-thiazolidin-2-yl)-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1N1S(=O)(=O)CCC1 DWQKZCIMVWJIBS-UHFFFAOYSA-N 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 230000003712 anti-aging effect Effects 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- JFRGVHDKQGKGOJ-UHFFFAOYSA-N methyl 4-(1,1-dioxo-1,2-thiazolidin-2-yl)-3-methylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC=C1N1S(=O)(=O)CCC1 JFRGVHDKQGKGOJ-UHFFFAOYSA-N 0.000 claims 1
- RTHZGZMREZPJRL-UHFFFAOYSA-N n-(diaminomethylidene)-4-(1,1-dioxo-1,2-thiazolidin-2-yl)-2-methyl-5-methylsulfonylbenzamide Chemical compound C1=C(C(=O)NC(N)=N)C(C)=CC(N2S(CCC2)(=O)=O)=C1S(C)(=O)=O RTHZGZMREZPJRL-UHFFFAOYSA-N 0.000 claims 1
- GNHBQRQBQXZITB-UHFFFAOYSA-N n-(diaminomethylidene)-4-(1,1-dioxo-4-phenyl-1,2-thiazolidin-2-yl)-2-methyl-5-methylsulfonylbenzamide Chemical compound C1=C(C(=O)NC(N)=N)C(C)=CC(N2S(CC(C2)C=2C=CC=CC=2)(=O)=O)=C1S(C)(=O)=O GNHBQRQBQXZITB-UHFFFAOYSA-N 0.000 claims 1
- ZEXSKAVDDIBBGH-UHFFFAOYSA-N n-(diaminomethylidene)-4-(1,1-dioxothiazinan-2-yl)-2-methyl-5-methylsulfonylbenzamide Chemical compound C1=C(C(=O)NC(N)=N)C(C)=CC(N2S(CCCC2)(=O)=O)=C1S(C)(=O)=O ZEXSKAVDDIBBGH-UHFFFAOYSA-N 0.000 claims 1
- LRNHWVUUAXXLSL-UHFFFAOYSA-N n-(diaminomethylidene)-4-(3,3-dimethyl-1,1-dioxo-1,2-thiazolidin-2-yl)-2-methyl-5-methylsulfonylbenzamide Chemical compound C1=C(C(=O)NC(N)=N)C(C)=CC(N2S(CCC2(C)C)(=O)=O)=C1S(C)(=O)=O LRNHWVUUAXXLSL-UHFFFAOYSA-N 0.000 claims 1
- YQJFRCKAROSGNN-UHFFFAOYSA-N n-(diaminomethylidene)-4-[4-(4-fluorophenyl)-1,1-dioxo-1,2-thiazolidin-2-yl]-2-methyl-5-methylsulfonylbenzamide Chemical compound C1=C(C(=O)NC(N)=N)C(C)=CC(N2S(CC(C2)C=2C=CC(F)=CC=2)(=O)=O)=C1S(C)(=O)=O YQJFRCKAROSGNN-UHFFFAOYSA-N 0.000 claims 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 0 CC(*)(C(*)(*)**1)N(c2c(*)c(*)c(C(I)=O)c(*)c2*)S1(=O)=O Chemical compound CC(*)(C(*)(*)**1)N(c2c(*)c(*)c(C(I)=O)c(*)c2*)S1(=O)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004054847A DE102004054847A1 (de) | 2004-11-13 | 2004-11-13 | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| PCT/EP2005/011595 WO2006050830A1 (de) | 2004-11-13 | 2005-10-29 | Substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008519783A JP2008519783A (ja) | 2008-06-12 |
| JP2008519783A5 true JP2008519783A5 (enExample) | 2008-12-11 |
Family
ID=35502583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540535A Ceased JP2008519783A (ja) | 2004-11-13 | 2005-10-29 | 置換ベンゾイルグアニジン類、それらの製造法及び医薬又は診断薬としての使用、並びにそれらを含む医薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7772262B2 (enExample) |
| EP (1) | EP1812412B1 (enExample) |
| JP (1) | JP2008519783A (enExample) |
| DE (2) | DE102004054847A1 (enExample) |
| WO (1) | WO2006050830A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110118262A1 (en) * | 2008-07-08 | 2011-05-19 | Boehringer Ingelheim International Gmbh | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors |
| KR20170091783A (ko) | 2008-12-31 | 2017-08-09 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법 |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| AU2013304812B2 (en) | 2012-08-21 | 2016-06-09 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| SMT201900386T1 (it) | 2013-04-12 | 2019-09-09 | Ardelyx Inc | Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| JP2020505333A (ja) | 2017-01-09 | 2020-02-20 | アルデリックス， インコーポレイテッド | Ｎｈｅ媒介性アンチポートの阻害薬 |
| AU2018205400C1 (en) | 2017-01-09 | 2026-01-15 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
| MX2020001412A (es) | 2017-08-04 | 2020-08-03 | Ardelyx Inc | Compuestos y métodos para tratar la hiperpotasemia. |
| ES3039169T3 (en) | 2019-02-07 | 2025-10-17 | Ardelyx Inc | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0589336T3 (da) * | 1992-09-22 | 1997-06-16 | Hoechst Ag | Benzylguanidiner, fremgangsmåde til deres fremstilling samt deres anvendelse som antiarytmetika |
| CN1328452A (zh) * | 1998-11-26 | 2001-12-26 | 默克专利股份公司 | 苯甲酰基胍类治疗非胰岛素依赖性糖尿病的用途 |
| DE10155075A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Cyclische Sulfonamide |
| DE10226462A1 (de) * | 2002-06-13 | 2003-12-24 | Aventis Pharma Gmbh | Fluorierte Cycloalkyl-derivatisierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| US7205318B2 (en) * | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
| US7371743B2 (en) * | 2004-02-28 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Carboxylic acid amides, the preparation thereof and their use as medicaments |
-
2004
- 2004-11-13 DE DE102004054847A patent/DE102004054847A1/de not_active Withdrawn
-
2005
- 2005-10-29 EP EP05806565A patent/EP1812412B1/de not_active Expired - Lifetime
- 2005-10-29 WO PCT/EP2005/011595 patent/WO2006050830A1/de not_active Ceased
- 2005-10-29 DE DE502005003873T patent/DE502005003873D1/de not_active Expired - Lifetime
- 2005-10-29 JP JP2007540535A patent/JP2008519783A/ja not_active Ceased
-
2007
- 2007-05-14 US US11/748,166 patent/US7772262B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2315041C2 (ru) | Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения | |
| JP2005529182A5 (enExample) | ||
| JP2022000482A5 (enExample) | ||
| JP2005522438A5 (enExample) | ||
| JP2014502979A5 (enExample) | ||
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP2004525117A5 (enExample) | ||
| CN1479734A (zh) | 具有钾通道阻断作用的芳基化呋喃和噻吩甲酰胺 | |
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| CA2660529A1 (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
| RU96104356A (ru) | Производные амидина, обладающие активностью против синтетазы оксида азота (у) | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| JP2008504266A5 (enExample) | ||
| JP2007536224A5 (enExample) | ||
| EA020691B1 (ru) | Производные оксадиазола | |
| JP2005526138A5 (enExample) | ||
| JPWO2023195529A5 (enExample) | ||
| JP2017509694A5 (enExample) | ||
| RU2319692C2 (ru) | Производные тетрагидрокарбазола, способ получения производных тетрагидрокарбазола (варианты), их применение (варианты) и фармацевтическая композиция, обладающая активностью антагониста гонадотропин-рилизинг-гормона (варианты) | |
| CA2618511A1 (en) | Novel benzothiazolone derivatives | |
| JP2004525183A5 (enExample) | ||
| JP2009501745A5 (enExample) | ||
| RU2008119994A (ru) | Ингибиторы калиевых каналов | |
| JP2021534254A5 (ja) | 心臓弁疾患を治療するための医薬組成物 | |
| JP2019529487A5 (enExample) |